Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
4D Pharma LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 110.00p 105.50p 114.50p 114.50p 114.50p 114.50p 37 16:35:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -24.0 -31.4 - 72.04

4D Pharma Share Discussion Threads

Showing 226 to 247 of 250 messages
Chat Pages: 10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
08/1/2019
09:00
Two new NEDs having held senior positions at top Pharma cos.. Xencor (XNCR 2.2bn valuation) and Celgene (CELG 61bn valuation). Something big is brewing here imo. watch this space.
someuwin
08/1/2019
07:32
08 January 2019 4D pharma plc (the "Company" or "4D") Appointment of independent Non-Executive Directors 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the appointment of Ed Baracchini, PhD, and Professor Axel Glasmacher, MD, as independent Non-Executive Directors with immediate effect. Ed Baracchini, PhD, was previously the Chief Business Officer at Xencor Inc. where he led strategic alliances and licensing. During his time at Xencor he negotiated license agreements with Novartis ($2.6B: immune-oncology bispecific antibodies), Novo Nordisk ($600M: drug discovery collaboration), Amgen ($500M: option and development agreement autoimmune disease antibody) among numerous others. Prior to that he served as SVP Business Development for Metabasis Therapeutics. Professor Dr. med. Axel Glasmacher was until recently Senior Vice President and Head of the Global Clinical Research and Development Hematology-Oncology at Celgene, where he has worked in various roles for more than ten years. His work at Celgene led to the approvals of Revlimid®, Idhifa®, and Vidaza® (haematological cancers). He also worked on the PD-L1 inhibitor durvalumab. Prior to Celgene, Professor Glasmacher worked within the fields of hematology-oncology at the University Hospital in Bonn. Duncan Peyton, 4D's Chief Executive Officer, commented: "We welcome Axel and Ed to our Board with great pleasure. Their collective experience will strengthen our commercial and therapeutic focus, as 4D accelerates development of its extensive pipeline in cancer and other immunological diseases."
someuwin
07/1/2019
09:25
Chairman, CEO, Chief Scientific Officer and NXD spent collectively £310,563 buying DDDD stock last month.
someuwin
07/1/2019
08:41
07 January 2019 4D pharma plc (the "Company" or "4D") Collaboration with MD Anderson Cancer Center 4D pharma and MD Anderson Cancer Center to Evaluate Live Biotherapeutics in Solid Tumours 4D pharma plc (AIM: DDDD) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings. The alliance brings together MD Anderson's translational medicine and clinical research capabilities with 4D's expertise in the discovery and development of Live Biotherapeutics. The collaboration will initially assess 4D's lead oncology candidate, MRx0518, as a potential treatment for solid tumours. The first clinical study, an open label Phase I study of MRx0518 in combination with Keytruda(R) and conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ., USA, has been initiated and is due to open shortly. The study will enrol up to 132 patients with metastatic cancer across multiple histologies (non-small cell lung cancer, renal cell carcinoma, bladder cancer and melanoma) who have failed prior anti-PD-1 therapy. Subsequent studies are also being planned under the collaboration, including using MRx0518 in combination with stereotactic body radiotherapy (SBRT) for the treatment of pancreatic cancer. Duncan Peyton, 4D's Chief Executive Officer, commented: "This alliance will provide a strong and long-term foundation for the development of 4D's Live Biotherapeutics in cancer." He added, "The current study, which will be one of the first Live Biotherapeutic programmes to reach the clinic in the immuno-oncology space, represents an important step forward in the development of MRx0518 and 4D's broader oncology franchise. We look forward to continuing to work with our partners at MD Anderson to progress this study and help bring this therapy to patients." Live biotherapeutics employ strains of gut bacteria that have been isolated from healthy human donors, and which are encapsulated, administered orally and delivered to the gut as a therapeutic. Each strain is selected for its functionality to perform a specific role in combatting a disease. "MD Anderson is focused on providing the best possible care for cancer patients, including implementing the latest new treatment modalities," said Shubham Pant, MBBS, associate professor of Investigational Cancer Therapeutics at MD Anderson. "The gut microbiome has emerged as an important next-generation target in cancer therapy and we hope that live biotherapeutics will have the potential to make a significant difference for patients across a range of cancers."
someuwin
23/12/2018
21:39
pyramid scheme.
rjmahan
23/12/2018
09:52
Initiative Q is an attempt by ex-PayPal guys to create a new payment system instead of payment cards that were designed in the 1950s. The system uses its own currency, the Q, and to get people to start using the system once it's ready they are allocating Qs for free to people that sign up now (the amount drops as more people join - so better to join early). Signing up is free and they only ask for your name and an email address. There's nothing to lose but if this payment system becomes a world leading payment method your Qs can be worth a lot. If you missed getting bitcoin seven years ago, you wouldn't want to miss this.Here is my invite link: https://initiativeq.com/invite/ysfoTKwF2This link will stop working once I'm out of invites. Let me know after you registered, because I need to verify you on my end.
sparky333
20/12/2018
10:47
mustau - Agreed and market seems to have noted with selling pressure (all be it small) building again - New target dwonside?
pugugly
19/12/2018
08:49
With all these director buys can’t be much news on the horizon in the near term.
mustau
13/12/2018
09:49
Well, that didn't make the ducks fly off the water. f
fillipe
13/12/2018
08:48
Why would you sell when directors have just bought nearly 250,000 between themTraders baffle me
sparky333
13/12/2018
07:59
Wow directors spending a lot of cash, boded well
sparky333
13/12/2018
07:59
Looks like £1.50 today?
miahkaysor
12/12/2018
19:27
JH Yep some very generous pi's paying 50p premium to the seller so the mm has cleaned up as normal. Not my style. If they pay for a block I will not pay more than 10% usually regardless of the overall company. Most of the time it serves me well, this time I missed out on 30p a share profit which is massive in this market
dave4545
12/12/2018
19:10
Rebound you mean...
babbler
12/12/2018
17:57
Nice retrace today.
sparky333
12/12/2018
14:06
"One measure of success of our research is the development of our intellectual property estate and 4D continues to lead the field. We now have 355 granted patents across 46 patent families. As our teams uncover new bacteria that are therapeutically relevant, and unpick the mechanism of action or develop novel production techniques, the intellectual property estate will continue to grow in size and value."
someuwin
12/12/2018
12:12
Well Dave ooks like you missed out on a good trade worrying about the Mms Xmas
john henry
12/12/2018
12:12
The current best bid/ask in show is 104p v 113p. A 37.5k lot was taken @ 109.35p, 1148hrs. f
fillipe
12/12/2018
12:09
Well said researchanalyst1! f
fillipe
12/12/2018
10:16
It's early Xmas gifted me also, so far just today. Plenty more to come during the remainder of this week. I'll be happy to receive a daily helping of steady up-tickings, ahead of the pudding on the 25th. f
fillipe
12/12/2018
10:14
No shortage of cash... Cash and cash equivalents and short-term deposits at 30 June 2018 of GBP36.6 million.
someuwin
12/12/2018
10:07
Yeah never hit my buy point Some people are too generous. mm gets stock at 75p and people paying 90p+ in this market for me is giving mm a early xmas gift.
dave4545
Chat Pages: 10  9  8  7  6  5  4  3  2  1
Your Recent History
LSE
DDDD
4D Pharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190119 22:35:30